Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

Gautam Borthakur, E. Lin, Nitin Jain, Elihu E. Estey, Jorge E. Cortes, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Sherry Pierce, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with corebinding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.

Original languageEnglish (US)
Pages (from-to)3217-3221
Number of pages5
JournalCancer
Volume115
Issue number14
DOIs
StatePublished - Aug 18 2009
Externally publishedYes

Fingerprint

Core Binding Factors
Acute Myeloid Leukemia
Leukemia
Survival
Disease-Free Survival
Topoisomerase Inhibitors
Alkylating Agents
Chromosome Aberrations
Multivariate Analysis

Keywords

  • Acute myelogenous leukemia
  • Core-binding factor
  • Event-free survival
  • Matched analysis
  • Overall survival
  • Therapy-related

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. / Borthakur, Gautam; Lin, E.; Jain, Nitin; Estey, Elihu E.; Cortes, Jorge E.; O'Brien, Susan; Faderl, Stefan; Ravandi, Farhad; Pierce, Sherry; Kantarjian, Hagop.

In: Cancer, Vol. 115, No. 14, 18.08.2009, p. 3217-3221.

Research output: Contribution to journalArticle

Borthakur, G, Lin, E, Jain, N, Estey, EE, Cortes, JE, O'Brien, S, Faderl, S, Ravandi, F, Pierce, S & Kantarjian, H 2009, 'Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia', Cancer, vol. 115, no. 14, pp. 3217-3221. https://doi.org/10.1002/cncr.24367
Borthakur, Gautam ; Lin, E. ; Jain, Nitin ; Estey, Elihu E. ; Cortes, Jorge E. ; O'Brien, Susan ; Faderl, Stefan ; Ravandi, Farhad ; Pierce, Sherry ; Kantarjian, Hagop. / Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. In: Cancer. 2009 ; Vol. 115, No. 14. pp. 3217-3221.
@article{9d8a591eaa4641cbb0d3873ae425b195,
title = "Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia",
abstract = "BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with corebinding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9{\%}. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.",
keywords = "Acute myelogenous leukemia, Core-binding factor, Event-free survival, Matched analysis, Overall survival, Therapy-related",
author = "Gautam Borthakur and E. Lin and Nitin Jain and Estey, {Elihu E.} and Cortes, {Jorge E.} and Susan O'Brien and Stefan Faderl and Farhad Ravandi and Sherry Pierce and Hagop Kantarjian",
year = "2009",
month = "8",
day = "18",
doi = "10.1002/cncr.24367",
language = "English (US)",
volume = "115",
pages = "3217--3221",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "14",

}

TY - JOUR

T1 - Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

AU - Borthakur, Gautam

AU - Lin, E.

AU - Jain, Nitin

AU - Estey, Elihu E.

AU - Cortes, Jorge E.

AU - O'Brien, Susan

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Pierce, Sherry

AU - Kantarjian, Hagop

PY - 2009/8/18

Y1 - 2009/8/18

N2 - BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with corebinding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.

AB - BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with corebinding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.

KW - Acute myelogenous leukemia

KW - Core-binding factor

KW - Event-free survival

KW - Matched analysis

KW - Overall survival

KW - Therapy-related

UR - http://www.scopus.com/inward/record.url?scp=68549123422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549123422&partnerID=8YFLogxK

U2 - 10.1002/cncr.24367

DO - 10.1002/cncr.24367

M3 - Article

C2 - 19441109

AN - SCOPUS:68549123422

VL - 115

SP - 3217

EP - 3221

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 14

ER -